Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab with TPE induction and XPE chemoradiation in SCCHN
NCT01588431Phase 2Completed
- Sponsor
- UT Health San Antonio
- Start
- Dec 2011
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in squamous cell carcinoma of the head and neck (HNSCC), sponsored by UT Health San Antonio. Started Dec 2011; status: completed.
02
Drugs
bevacizumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT01588431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01588431.